Coating technique for deposition of drug substance on a substrate

• US 20030203027A1
• Filed: 04/26/2002
• Published: 10/30/2003
• Est. Priority Date: 04/26/2002
• Status: Abandoned Application

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Verreck, Geert, Rosenblatt, Joel, Liland, Alfred
• Application Number:
  US10/134,305
• Publication Number:
  US 20030203027A1
• Time in Patent Office: Days
• US Class Current: 424/471
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61K 9/2893 Tablet coating processes mechanical aspects A61J3/06

Abstract

The present invention relates to a multi-layered, physiologically tolerated oral dosage form for pharmaceutically active compounds. The dosage form comprises a central core, a middle layer, and an outer shell, at least one of which includes at least one pharmaceutically active substance. By varying the diameter of the core, a different middle layer volume is obtained within a fixed outer shell dimension. This gives the ability to obtain different dosage strengths for one composition without the need of reformulation work. The oral dosage form is produced in a single-step, continuous process by coating the core with the middle layer and the outer shell.

Claims

1. A multi-layered oral dosage form for pharmaceutically active substances, comprising a central core having a volume;

a middle layer surrounding said core; and

an outer shell, at least one of said central core, said middle layer and said outer shell includes at least one pharmaceutically active substance, wherein the volume of said central core is selected to obtain a desired volume of said middle layer within a predetermined dimension of said outer shell.

2. The form according to claim 1, wherein said central core is a solid cylinder.

3. The form according to claim 1, wherein said central core is a hollow cylinder.

4. The form according to claim 3, wherein said hollow cylinder is perforated.

5. The form according to claim 1, wherein said central core includes said at least one pharmaceutically active substance.

6. The form according to claim 1, wherein said middle layer includes said at least one pharmaceutically active substance.

7. The form according to claim 1, wherein said outer shell includes said at least one pharmaceutically active substance.

8. The form according to claim 1, wherein said core includes a carrier of at least one compound selected from the group consisting of a thermoplastic pharmacologically acceptable solid polymer that melts or softens upon heating, a blend of thermoplastic pharmacologically acceptable polymers that melt or soften upon heating, and excipients.

9. The form according to claim 8, wherein the carrier is poly (vinylidene fluoride).

10. The form according to claim 1, wherein said shell includes a carrier of at least one compound selected from the group consisting of a thermoplastic pharmacologically acceptable solid polymer that melts or softens upon heating, a blend of thermoplastic pharmacologically acceptable polymers that melt or soften upon heating, and excipients.

11. The form according to claim 10, wherein the carrier is selected from the group consisting of hydroxyalkylcellulose, polymethacrylate, copolymers of polyvinylpyrrolidome, and vinyl esters.

12. The form according to claim 1, wherein the middle layer includes a carrier of at least one compound selected from the group consisting of a thermoplastic pharmacologically acceptable polymer that melts or softens upon heating, a blend of thermoplastic pharmacologically acceptable polymers that melts or softens upon heating, a thermoplastic pharmacologically acceptable wax that melts or softens upon heating, a blend of thermoplastic pharmacologically acceptable waxes that melts or softens upon heating, a blend of said polymers and said waxes, non-polymeric liquids, and excipients.

13. The form according to claim 12, wherein the carrier is a polyethylene glycol with a molecular weight in the range from about 200 Da to about 20,000 Da.

14. The form according to claim 1, wherein said at least one pharmaceutically active substance is selected from the group consisting of analgesic and anti-inflammatory drugs, anti-arrhythmic drugs, antibacterial and antiprotozoal agents, anti-coagulants, antidepressants, anti-diabetic drugs, anti-epileptic drugs, antifungal agents, antihistamines, anti-hypertensive drugs anti-muscarinic agents, antineoplastic agents and antimetabolites, anti-migraine drugs, anti-Parkinsonian drugs, antipsychotic, hypnotic and sedating agents, anti-stroke agents, antitussive agents, antivirals, beta-adrenoceptor blocking agents, cardiac inotropic agents, corticosteroids, diuretics, enzymes, essential oils, gastro-intestinal agents, immunosurpressive agents, haemostatics, lipid regulating agents, local anaesthetics, opioid analgesics, parasympathomimetics and anti-dementia drugs, peptides and proteins, sex hormones, stimulating agents and vasodilators.

15. The form according to one of claims 8, 10 or 12, wherein said thermoplastic pharmacologically acceptable solid polymer and polymers are at least one compound selected from the group consisting of cellulose ethers, hydroxyalkylcelluloses, carboxyalkylcelluloses, alkali metal salts of carboxyalkylcelluloses, cellulose phthalates, starches, thermoplastic starches, starch derivatives, sugar alcohols, pectines, chitin derivatives, polysaccharides and alkali metal and ammonium salts thereof, carrageenans, galactomannans, tragacanth, agar-agar, gummi arabicum, guar gummi and xanthan gummi, polyhydroxyalkylacrylates, polyhydroxyalkylmethacrylates, polyacrylates, polymethacrylates (eudragit types), polyacrylic acids and salts thereof, polymethacrylic acids and salts thereof, methacrylate copolymers, polyvinylalcohol, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone, vinyl esters, polyalkylene oxides and copolymers of ethylene oxide and propylene oxide, polyalcohols, polyoxyethylene castor oils, polyoxyethylene stearates, polyoxyethylene alkyl ethers, sesame oil, carnauba wax, mono- and diglycerides, triglycerides of the C12-, C14-, C16- and C18-fatty acids, polyalkylenes, polyvinylidene, fluoropolymers, polyurethanes, polyesters, polyamides, polylactic acid, polycaprolactone, polyglycolic acid, copolymers of polylactic acid and polycaprolactone, copolymers of polylactic acid and polyglycolic acid, copolymers of polycaprolactone, and polyglycolic acid, polydioxanone, copolymers of polydioxanone and polyglycolide, and copolymers of polydioxanone and polycaprolactone.

16. The form according to one of claims 8, 10 or 12, wherein said excipients are at least one compound selected from the group consisting of plasticizers, lubricants, flavors, colorants, stabilizers, complexing agents, surfactants and disintegrants.

17. A method for producing a multi-layered oral dosage form for pharmaceutically active substances, wherein the outer dimension of said form is fixed and the volume of a middle layer is selectively variable, comprising the steps of:

providing a core having a selected volume;

coating said core with said middle layer, wherein the total combined volume of said core and said middle layer is a predetermined volume; and

coating said middle layer with an outer shell to obtain said fixed outer dimension, wherein at least one of said core, said middle layer and said outer shell includes at least one pharmaceutically active substance.

18. The method according to claim 17, wherein at least one of the coating steps includes extruding.

19. The method according to claim 17, wherein at least one of the coating steps includes dipping.

20. The method according to claim 17, wherein the step of providing a core includes the step of producing the core by melt extrusion.

21. The method according to claim 17, wherein the step of providing a core includes the step of producing the core by solution spinning.